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of life (QoL) and the ability to work (WA) too. Till now in the Slovak Republic there 
was not realised the study oriented on the both mentioned categories. Methods: 
102 patients with LC were studied. The average of age was 50.3 y., weight – 78.3 kg, 
height – 175.1, duration of illness – 2.4 y., symptoms of illness before diagnosis – 1.2 
y. Metastases were present in 72 patients. 4 patients were mentioned as strong pes-
simists, 10 predominant pessimists, 9 neither pessimists nor optimists, 61 predomi-
nant optimists, and 18 strong optimists. QoL and the ability to work was evaluated 
by means of the numeric scale from 0 to 10 (0-the worst, 10- the best) by patients 
themselves. Results: The QoL was evaluated in these domains: in the time of good 
health – 8-21, in the time of diagnosis – 2.82, in the current time – 3.71. The WA had 
these results: in time of good health – 8.89, in the time of diagnosis – 5.08, and in 
the current time – 2.17. The impact of treatment on the QoL was 2.49 and on the 
patients families QoL it was 2.75. The willingness to pay for perfect cure was 92.35 € 
per month (the average salary in Slovakia in 2013 was 824 € ). ConClusions: LC has 
a great impact on QoL and on the WA too. There was a strong correlation between 
QoL and WA, although the WA has the later onset as QoL. Our research confirmed 
the importance of early diagnosis and high effective treatment of this disease.
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objeCtives: To validate the short version of the QLQ-C30 obtained for patients with 
non-small-cell lung cancer in patients with head and neck, prostate, breast or cervix 
cancer. Methods: We analysed data of 636 patients distributed: 237 diagnosed 
with head and neck cancer, 146 diagnosed with breast cancer, 140 diagnosed with 
cervix cancer and 113 diagnosed with prostate cancer. The analysis followed a 4-step 
approach. First, we conducted a Mokken nonparametric item response analysis 
to ascertain the QLQ-C30 dimensionality and separate several scale if appropri-
ate. Second, we conducted a parametric Samejima’s graded response model (GRM) 
to assess the item characteristics and information for each scale. Third, we did 
a confirmatory factor analysis (CFA) to test the scales unidimensionality and to 
obtain standardised factor loadings to suggest a reduced version of the QLQ. Finally, 
we assessed the discriminative validity of the reduced version by using receiver-
operator curve (ROC) analysis. Results: Mokken analysis of the QLQ-C30 resulted 
in a unidimensional scale, with an overall scalability defined a medium scale. The 
unconstrained GRM showed that most items presented appropriate difficulty and 
discrimination parameters. The CFA supported an underlying unidimensional 
latent structure for the whole QLQ-C30 (CFI = 0.98; RMSEA = 0.05) with modifica-
tion indexes pointing to important redundancy of information. The selection of 
items with standardized factor loadings > 0.70 lead to a 6-item QLQ that showed 
good discriminative validity against independent criteria of quality of life (ROC 
area = 0.76; 95% CI = 0.72 to 0.80) as compared with the values for the whole scale 
(ROC area = 0.70; 95% CI = 0.66 to 0.74). ConClusions: The EORTC reduced scale 
was validated in this study; it presents good psychometric properties and includes 
a unidimensional structure of patient-perceived quality of life.
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objeCtives: Surgery for breast cancer has a substantial impact on a woman’s 
health-related quality of life (HR-QOL). The NIH and EORTC advocate treatment 
with breast conserving therapy (BCT) for women with early stage breast cancer. The 
aim of this study was to understand the shared surgical decision-making process 
from the patients’ perspective by implementing qualitative methods. Methods: 
All participants were recruited and consented from a single center. Inclusion criteria 
included women who selected BCT over mastectomy. Utilizing an interview guide, 
women were asked to share their experience with all aspects of decision-making 
related to breast cancer treatment. Interviews were audio-taped, transcribed, and 
coded with NVIVO8. Qualitative data were further analyzed to identify factors 
influencing decision-making regarding BCT. A comparative matrix analysis was 
conducted to further evaluate women’s appraisal of their surgical decision-mak-
ing process and how this impacted their long-term HR-QOL. Results: Nineteen 
patients were included in the analysis. The mean age was 58.3 (+ 12.2) years, 52.9% 
were married, 84.2% were Caucasian, 68.4% were currently employed and 31.6% 
had a family history of breast cancer, 10.4% diagnosed with Stage 0, 52.6% stage 
I and 36.8% stage II breast cancer. Factors contributing to decision-making were 
dichotomized into satisfied (n= 11) or dissatisfied (n= 8). Satisfied patients were 
further categorized as either (i) positive outlook n= 2; (ii) acceptance of choice n= 9; 
Dissatisfied patients were further categorized as (i) experiencing regret n= 4; (ii) fear 
of recurrence n= 4. ConClusions: As decision-making needs vary by individual 
women, a personalized decision-making approach is an essential factor to improve 
HR-QOL among women with early stage breast cancer. Additional prospective quan-
titative studies of the preoperative decision-making and post-operative HR-QOL are 
necessary, as these findings may compliment existing outcomes research.
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1) estimate each patient’s longitudinal HRQoL trajectory before the first SRE using 
repeated measures analysis; 2) calculate how SREs affect HRQoL changes. Results: 
We found statistically significant declines in utility scores after all three types of 
SREs with an adjusted mean change of -0.06 (95% CI [-0.10, -0.02]) for “radiotherapy/
surgery” (N= 107), -0.20 (95% CI [-0.36, -0.04]) for “fractures” (N= 31) and -0.24 (95% 
CI [-0.39, -0.08]) for “compression” (N= 23). “Fractures” and “compression” affected 
a number of FACT-P domains and total score to a clinically meaningful and statisti-
cally significant extent. Compression had the broadest impact, affecting 7 out of 9 
FACT-P domains and induced a mean decrease in the FACT-P total score of -16.96 
(95% CI [-26.47, -7.44]). Radiotherapy/surgery was associated with a statistically 
significant decline in physical (-1.28, 95% CI [-2.06, -0.50]) and functional well being 
(-1.51, 95% CI [-2.37, -0.64]), and improvement in social well being (1.26, 95% CI [0.60, 
1.91]). Full results will be presented. ConClusions: The presence of SREs was 
significantly associated with poorer HRQoL in this patient population. Any therapy 
reducing or delaying the occurrence of SREs may slow down the observed HRQoL 
decline in mCRPC patients.
PCN207
sustaiNable MeasureMeNt of resPoNse shift iN Prostate CaNCer 
PatieNts: adjustiNg health related Quality of life with the  
theN-test
ten Ham R.M.1, Wilson L.S.2, Broering J.M.2, Cooperberg M.R.3, Carroll P.3
1Utrecht University, Utrecht, The Netherlands, 2University of California San Francisco, San 
Francisco, CA, USA, 3University of California, San Francisco, San Francisco, CA, USA
objeCtives: Patients diagnosed with prostate cancer (PCa) have similar survival 
rates across treatments, making treatments choices based on health related quality 
of life (HRQoL) more important. Objective was to increase HRQoL usage, sustain-
ability and reliability measurement over time for use in cost–effectiveness analyses 
by investigating the occurrence of response shift (RS) in PCa patients. Never before 
has RS been measured over this long a time in PCa patients, not limited by few 
available treatment options. Methods: A prospective cross sectional cohort study 
was started in January of 2012 with 1,720 CAPSURE patients using the SF-36 and 
UCLA-Prostate Cancer Index (PCI). In January of 2012 patient were asked to fill out 
questionnaires asking about their perceived HRQoL at time of diagnosis (then score) 
and current HRQoL (post-score). These scores were matched to previous collected 
scores at baseline (pre-score), ranging from 3 months to 20 years. RS (then-pre score), 
True Change (TC= post-then score) and Felt Change (FC= post-then) were calculated 
and compared with t-tests in different questionnaire domains. Linear regression 
was used to explore relations between scores and patient characteristics. Results: 
RS and FC are found to be negative overall for SF-36 (RS:-3.6/-14.5 TC:-8.1/1.8 
FC:-3.0/-22.7) and PCI (RS:-4.0/-30.2 TC:-20.2/0.07 FC:-3.6/-49.8), showing significant 
difference (P< 0.05). Significant difference was also seen over the whole time range 
between post-scores and RS-adjusted-post-scores for SF-36 and PCI. A difference 
was found between recurrence and non-recurrence in both questionnaires (ranging 
0/-4.0), although not significant. RS over time did not show change. ConClusions: 
Mean negative RS scores were found in this population using SF-36 and PCI, indi-
cating over reporting in retrospective collected data. It is recommended physicians 
and researchers adjust found HRQoL scores with RS values found in this study, 
to increase usage, sustainability and reliability of retrospective collected HRQoL-
scores. Further research is needed to investigate RS dependency on other variables 
or characteristics.
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objeCtives: Multiple myeloma is common in older adults and its incidence increases 
after the age of 60 (under the age of 40, it occurs rarely, < 2%). In SK approx. 400 new 
cases have been diagnosed and in the treatment there is in average 1500 patients. 
Research aim was to find out the impact of the disease on particular items of Quality 
of patients´ lives. Methods: Sample: research consisted of pacienti diagnosed with 
the disease of multiple myeloma. We distributed 120 questionnaires and compiled 82 
questionnaires (68,33%). There were 36 men (43,90%) and 46 women (56,10%). Their age 
was between 40 and more. We utilised standardised questionnaire of quality of life, 
Quality of Life-BREF (WHOQOL-BREF). Its first part included 24 items in four domains 
(physical health, psychological health, social relationships, and environment) and two 
items of overall evaluation. Numerical scales were signed in the answers in the follow-
ing way: the least auspicious answer had the smallest value and the most auspicious 
answer had the biggest numerical value (range 1 – 5). The results of respondents were 
compared to population norms of the WHOQOL-BREF domains. Results: In majority 
of items, the answers of the respondents do not differ very much in comparison with 
the average score of WHOQOL-BREF. Two items mostly differ from the average score 
most: domain of physical health – pain, where the average of 2.5 lowered in compari-
son to population norm of 4.03. The domain psychological health – negative emo-
tions: where the average of 2.00 was lower in comparison to the population norm of 
3.47. ConClusions: Prompt diagnostics of multiple myeloma significantly increases 
the possibility of the treatment to be successful. It also prolongs and improves quality 
of patient life. Research finding points out the reality that MM does not have the same 
impact on all domains of quality of life.
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objeCtives: The current incidence and mortality of lung cancer (LC) in adult 
patients in Slovakia ranges from about 57.3 resp. 50.3 in men and 10.6 resp. 7.6 
in women per 100000 inhabitants. The lung cancer has a great impact on quality 
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objeCtives: Next Generation Sequencing (NGS) offers a potentially powerful plat-
form for extremely sensitive, high-throughput, multiplex, quantitative detection of 
nucleic acid biomarkers. While NGS currently represents a small portion of global 
clinical molecular diagnostic testing, new funding and reimbursement initiatives 
promise to accelerate its clinical utilization. Given increasing numbers of predic-
tive/ prognostic biomarkers but limited tissue and need for less invasive sample 
acuisition, NGS has the potential to transform personalized medicine (PM) and 
companion diagnostics. The current study characterized global NGS availability and 
reimbursement trends. Health technology assessments (HTAs) for NGS and other 
relevant multiplex/ gene panel tests were also studied for evolving evidence require-
ments. Methods: Key health care provision, HTA agency, and payer websites in the 
EU, US, Australia and Canada were reviewed to identify NGS funding and reimburse-
ment initiatives, and relevant HTAs. In addition, a limited number of stakeholder 
interviews were conducted to help further characterize the evolving global NGS 
landscape. Results: A number of NGS funding and reimbursement initiatives 
were identified, especially France, Germany, UK, US and Australia. Initiatives have 
been mainly centered on funding of pilot clinical utility demonstrations through 
research and clinical use. In Germany and US, specific initiatives are underway to 
develop specific NGS reimbursement codes and payment rates. A number of HTAs 
for NGS and other multiplex/ gene panel test platforms were identified, primarily for 
oncology, cardiovascular, infectious disease, inherited disease, and neuropsychiatry 
applications. Key HTA concerns include test clinical utility, cost-effectiveness, real-
world reproducibility and equity of access given potential cost. ConClusions: 
Payers and providers increasingly recognize NGS as enabling expanded adoption 
of PM approaches. As PM expands with increasing numbers of clinically actionable 
biomarkers, ensuring that test evidence development is aligned with expectations, 
and expectations with reality are key steps. Further, developing reimbursement/ 
funding mechanisms to support testing uptake will be critical in all markets.
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By 2030, 50% of all deaths are expected to be caused by oncology, or cardiovascular 
diseases. Research and development therefore continues to evolve in these areas to 
provide a better answer to complex medical needs. As a consequence, the definition 
of innovation is evolving, going from therapeutic drugs with a new mode of action 
to novel biotechnologies, biological therapeutics, and vaccination. objeCtives: 
We aim to investigate how therapies for oncology and cardiovascular diseases are 
expected to evolve in future into technologies that transform the concept of innova-
tion. Methods: Data were extracted from Citeline to assess the scale of therapies 
in development including: vaccines, stem cells, antibodies, reformulation of combi-
nation therapy, gene therapy and RNAi. Results: In oncology, across the selected 
novel therapies, there are over 670 trials in preclinical to phase 3 of development. 
Vaccines have a higher rate of development with over 200 products in preclinical 
development to phase 3. Other areas of development include antibodies, and gene 
therapy, with over 30 therapies in phase 2 trials alone. Meanwhile, cardiovascular 
disease has fewer ongoing ‘novel therapy’ trials compared to oncology (around 75% 
fewer trials). The main areas of development include reformulation of fixed dose 
combinations, and stem cell research (a total of 60 trials, and 53 trials in preclinical 
to phase 3 respectively). The trend in innovation for cardiovascular disease instead 
tends to be focussed on integrated technology and medical devices. ConClusions: 
While we are fairly acquainted with the current evaluation methods and relevance 
of clinical and economic evidence of traditional therapies, the emergence of new 
technologies creates uncertainties around how they will be assessed by payers. For 
example, demonstrating the value of vaccines (which avoid illness) is difficult to 
express. Industry must now consider factors outside of the current remit to prepare 
for successful market access.
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objeCtives: It is controversial to use 5-year survival estimates to assess the pro-
gress in cancer prevention and control. The study aimed to analyze associations 
between 5-year survival, and two standard measures of cancer burden, incidence 
and mortality, based on publicly available population cancer statistics in England 
and Wales. Methods: Sex-specific mortality and incidence of 14 types of com-
mon cancer between 1976 to 1995 were obtained from a national database on 
the UK Office for National Statistics website. Sex-specific 5-year survival data 
retrieved from the Cancer Research UK website databases. The relationships 
between 5-year survival, and incidence and mortality were estimated based on 
both Pearson and Spearman correlation coefficients. Results: From 1976 to 1995, 
all male and female cancer types showed increased 5-year survival, ranged from 
0.2% (pancreas and lung cancers) to 16.6% (prostate cancer) for males, and from 
objeCtives: Colorectal cancer (CRR) is an important public health problem. The 
human and financial costs of this disease have prompted considerable research 
efforts to evaluate the ability of screening tests to detect the colorectal cancer at 
an early curable stage. It is now established that screening by faecal occult blood 
test (FOBT) in average-risk populations can detect asymptomatic colorectal cancers 
and precancerous lesions (high-risk adenomas). Methods: We have reviewed the 
evidence about the quality, accessibility, and cost of screening using the FOBT to 
reduce colorectal cancer mortality. Such databases as Medline, PubMed, EMBASE 
were used. Results: Faecal occult blood test screening benefits include reduc-
tion in CRR mortality, possible reduction in cancer incidence through detection 
and removal of colorectal adenomas and potentially, treatment of early colorectal 
cancers may involve less invasive surgery. Thus, implementation of biennial faecal 
occult blood test screening is an efficient use of health resources. ConClusions: 
The main objective for the improvement of cancer patients’ care is the introduction 
of national colorectal cancer screening programs based on evidence and available to 
people across the country. Introduction of clinical and cost-effectiveness screening 
methods in Ukraine and coordination of Ukrainian and world practices will provide 
timely and effective medical care for patients with CRR. In order to integrate these 
approaches into clinical practice based on evidence the clinical protocols are being 
developed.
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bACkgRound: There is ongoing debate over the extension of accelerated 
approval and conditional market authorisation initiatives, particularly for 
new cancer drugs in the US and Europe. This raises concerns for the benefit-
risk assessments of both regulators and payers when relying on early trial 
evidence. Methodological issues relating to immature clinical data and 
short-term follow-up, as well as the potential use of surrogate endpoints, 
may undermine these assessments and the resulting decisions made under 
conditions of uncertainty. In the context of health technology assessments 
(HTA) in the UK, we considered the impact on the probabilities of being the 
most effective and cost-effective treatment when reviewing available evi-
dence along the drug development and assessment processes. objeCtives: 
To conduct a retrospective analysis of four NICE technology appraisals in pri-
mary breast cancer for HER-2 positive women alongside a simulation study to 
evaluate the relative effectiveness and cost-effectiveness of selected drugs over 
time. Methods: We extracted data from TA107, TA108, TA109 and TA112 to ana-
lyse ‘snapshots’ of evidence at different time-points. Based on this example, we 
simulated individual patient characteristics and progression-free survival (PFS) 
times according to a predefined recruitment timeline. For both applied and simu-
lated datasets, we combined a network-meta-analysis and three-stage Markov 
economic model in WinBUGS to predict the joint impact of growing evidence net-
works on HTA results. The model allowed for different assumptions regarding the 
extrapolation of and the correlation between PFS and overall survival. Results: 
The magnitudes of credible intervals depended heavily upon the level of restriction 
used for follow-up. In addition, the performance of PFS as a surrogate endpoint 
strongly relied on the assumptions made on the correlation between the two 
endpoints. ConClusions: Our analysis highlighted the inherent limitations and 
risks of early assessments with a substantial increase in the uncertainty of treat-
ment acceptability at thresholds of £20K and £30K.
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objeCtives: Next Generation Sequencing (NGS) promises to find mutations 
(targets) in individual cancer patients, to subsequently assign targeted therapy. 
Currently, the technology itself is still in development and the effects on disease 
development, prognosis, or choice of therapy are still unclear. Besides informa-
tion for the current patient, additional (secondary) information for future patients 
can also become available. To accelerate the reimbursement process and have a 
NGS-panel available for patients in the earliest possible stage, early Technology 
Assessment (TA) is ongoing. In this project, we report on expert elicitation by 
means of scenario drafting, to provide qualitative and quantitative data to fill 
the evidence gaps in early cost-effectiveness modeling. Methods: The follow-
ing steps in a multi-parameter framework can be distinguished: 1) Identifying 
(dynamic) aspects having impact on adoption; 2) Brainstorm on possible sce-
narios (informal interviews with NGS experts); 3) Scenario construction; 4) 
Validation of scenarios (semi-structured questionnaires to European NGS-experts); 
5) Quantification into parameters for cost-effectiveness modeling. Results: 
Based on the interviews and questionnaires (n= 29), the most likely scenarios as 
patients interest in NGS (likelihood 66,5% ±28,1); organizational readiness (84,4 
±18,5); advantage of including RNA, and the demand from the clinic (needs of 
medical staff) were identified as drivers for NGS development. Possible barrier 
scenarios were: number of actionable targets (55,2 ±23,7); demonstrating clinical 
utility (50,4 ±31,4); current evidence generation (65,5 ±27,9); consensus on panel 
for reimbursement (40,3% ±24,1); and competition within the field (64,2 ±21,9). 
Clustering into parameters for cost-effectiveness modeling resulted in: “failures”, 
“compliance”, “uptake”, and “future information”. ConClusions: Although there 
are many issues to overcome to adopt NGS, the likelihood of NGS incorporation in 
clinical practice is very high. The “additional future information” is the most inter-
esting but complex variable to identify and to incorporate in cost-effectiveness 
modeling.
